Literature DB >> 16461991

Drug-induced urticarias.

Pascale Mathelier-Fusade1.   

Abstract

Drugs may cause urticaria by different mechanisms. The most well-known mechanism is the allergic reaction mediated by immunoglobulin (Ig)E antibodies, which induce acute generalized urticaria. Allergic reactions to beta-lactams are the most common cause of adverse drug reaction mediated by IgE antibodies. However, IgE antibodies are not always necessary to activate the release of mediators from mast cells and induce acute urticarias. Some drugs, such as opiates or codeine, act directly on mast cells, and others, such as aspirin and nonsteroidal anti-inflammatories, induce an exacerbation of chronic urticaria by a pharmacological mechanism involving the arachidonic acid metabolism. Additionally, angioedema is a wellknown complication of angiotensin-converting enzyme inhibitors by its action on bradykinin, which is a potent vasodilatator agent. Topical drugs, such as antibiotics, disinfectants, or anesthetics, may cause urticaria, which sometimes progresses to generalized urticaria and, more rarely, to anaphylactoid reactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461991     DOI: 10.1385/CRIAI:30:1:019

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  25 in total

1.  Amiodarone-induced angioedema.

Authors:  E Burches; F Garcia-Verdegay; M Ferrer; A Pelaez
Journal:  Allergy       Date:  2000-12       Impact factor: 13.146

2.  Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria.

Authors:  Riccardo Asero
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

Review 3.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

4.  Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.

Authors:  Joaquin Quiralte; Julio Delgado; Blanca Sáenz de San Pedro; Esperanza López-Pascual; Maria Angustias Nieto; Nancy Ortega; Jose Fernando Florido; José Conde
Journal:  Ann Allergy Asthma Immunol       Date:  2004-10       Impact factor: 6.347

5.  Chronic urticaria: diagnostic recommendations.

Authors:  C Bindslev-Lensen; A Finzi; M Greaves; J Camarasa; J P Ortonne; E Schöpf; D Tennstedt
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-05       Impact factor: 6.166

6.  [Adverse cutaneous reaction to celecoxib: 6 cases].

Authors:  D Murr; H Bocquet; H Lelouet; R M Fischer; J Revuz; A Cosnes
Journal:  Ann Dermatol Venereol       Date:  2003-05       Impact factor: 0.777

7.  Valsartan-induced angioedema.

Authors:  Brian K Irons; Ashwani Kumar
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

8.  [Orbital edema induced by psychotropic drugs?].

Authors:  Y Scrivener; B Cribier; C Le Coz; E Grosshans
Journal:  Ann Dermatol Venereol       Date:  1998-04       Impact factor: 0.777

Review 9.  Chlorhexidine anaphylaxis: case report and review of the literature.

Authors:  A B Krautheim; T H M Jermann; A J Bircher
Journal:  Contact Dermatitis       Date:  2004-03       Impact factor: 6.600

10.  [Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases].

Authors:  J-P Ducroix; S Outurquin; B Benabes-Jezraoui; V Gras; G Chaby; V Strunski; V Salle; A Smail; C Lok; M Andrejak
Journal:  Rev Med Interne       Date:  2004-07       Impact factor: 0.728

View more
  12 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 3.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

4.  Sublingual desensitization for buprenorphine hypersensitivity.

Authors:  Lisa M Stutius; Itai Pessach; Joanne Lee; Mindy S Lo; Sharon Levy; Patricia Schram; Miriam Schizer; Jackson Wong; Wanda Phipatanakul; Dale T Umetsu
Journal:  J Allergy Clin Immunol       Date:  2010-03-11       Impact factor: 10.793

Review 5.  Regulation of mast cell responses in health and disease.

Authors:  Alasdair M Gilfillan; Michael A Beaven
Journal:  Crit Rev Immunol       Date:  2011       Impact factor: 2.214

Review 6.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

8.  Neutrophilic urticaria: whole-body (111)In-leukocyte scan and histological correlation.

Authors:  Prakash Manoharan; Douglas Fullen; Anca Avram
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-05       Impact factor: 10.057

9.  Hyperlipidemia Is Associated with Chronic Urticaria: A Population-Based Study.

Authors:  Shiu-Dong Chung; Kuo-Hsien Wang; Ming-Chieh Tsai; Herng-Ching Lin; Chao-Hung Chen
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

10.  Prevalence and Causes of Childhood Urticaria.

Authors:  Meeyong Shin; Sooyoung Lee
Journal:  Allergy Asthma Immunol Res       Date:  2017-05       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.